Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus
Glaukos reported positive three-year results from its Phase 3 extension study (GLK-202-03) of Epioxa, its epi-on corneal cross-linking therapy for keratoconus, showing durable efficacy after a single treatment. Treated eyes sustained a 1.9 diopter improvement in maximum corneal curvature, with 29% and 20% of eyes gaining two or more and three or more lines of best-corrected visual acuity, respectively, and no serious adverse events through three years.
Key figures
- Drug Name
- Epioxa (riboflavin 5'-phosphate ophthalmic solution)
- Phase Of Trial
- Phase 3
- Subjects
- 35
- Study eyes
- 38
- Kmax improvement diopters
- 1.9
- Year3 visit completion pct
- 92%
- Eyes gaining 2plus lines bcva pct
- 29%
- Eyes gaining 3plus lines bcva pct
- 20%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.